<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-05-27T16:28:58Z</responseDate><request verb="GetRecord" identifier="oai:riuma.uma.es:10630/14558" metadataPrefix="rdf">https://riuma.uma.es/rest/oai/request</request><GetRecord><record><header><identifier>oai:riuma.uma.es:10630/14558</identifier><datestamp>2026-02-03T12:30:07Z</datestamp><setSpec>com_10630_2254</setSpec><setSpec>col_10630_37959</setSpec></header><metadata><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:riuma.uma.es:10630/14558">
      <dc:title>Increased Impulsivity following progressive nigral degenereation and chronic pramipexole treatment in an animal model of Parkinson's disease</dc:title>
      <dc:creator>Jiménez-Urbieta, Haritz</dc:creator>
      <dc:creator>Merino-Galan, Leire</dc:creator>
      <dc:creator>Rodriguez-Chinchilla, Tatiana</dc:creator>
      <dc:creator>Delgado-Alvarado, Manuel</dc:creator>
      <dc:creator>Quiroga-Varela, Ana</dc:creator>
      <dc:creator>Gago-Calderón, Belén</dc:creator>
      <dc:creator>Rodríguez-Oroz, María Cruz</dc:creator>
      <dc:subject>Parkinson, Enfermedad de</dc:subject>
      <dc:description>Dopamine agonists (DA) that are widely used to treat motor deficits in patients with Parkinson’s &#xd;
disease  (PD)  are  frequently  associated  with  the  development  of  abnormal-impulsive behaviors &#xd;
(AIB). The pathophysiology of AIB is poorly understood and there is a need for reliable animal &#xd;
models. We have analyzed the behavior of parkinsonian (injection of adeno-associated viral vectors (AAV) encoding for A53T mutated hα-syn in the substantia nigra compacta) and control (AAV-&#xd;
GFP  expression)  rats  under  chronic  treatment  with  the  D2/D3  receptor  DA  pramipexole  (PPX) &#xd;
during 4 weeks, in OFF and ON medication states,&#xd;
 using the 5-Choice Serial Reaction Time-Task (5-CSRTT). Before PPX treatment, the dopaminergic lesion increased the premature responses rate &#xd;
(waiting impulsivity) that was further increased with PPX during the 4 weeks of treatment in ON medication state and that was significantly higher than in control rats. A similar pattern of changes &#xd;
was observed in the variables related to attention (reduced accuracy in the responses and increased &#xd;
omissions). Premature response rate before and after treatment (both in ON and OFF medication) were  correlated.  In  turn,  premature  responses  before  treatment  and  in  OFF  correlated  with  the striatal  dopaminergic  depletion (Dopamine transporter  (DAT) immunochemistry). No significant changes  were  observed  in  OFF  medication  state  in  premature  responses  rate  respect  to  the pretreatment  state.  The  striatal  expression  of  FosB/ΔFosB inversely  correlated  with  the  DAT expression  and  was  higher in  the  lateral region  of  both  striata and  in  the shell  and  core  of  the nucleus accumbens in parkinsonian than in control rats. In conclusion, these results indicate that the dopaminergic  lesion is  a  risk  factor  to  develop  abnormal  impulsive behaviors  in  PD  under  DA treatment and   that this model could be a valid tool to investigate the pathophysiology of AIB in PD (DFG11/019, PI11/02109).</dc:description>
      <dc:date>2017-10-02T11:38:27Z</dc:date>
      <dc:date>2017-10-02T11:38:27Z</dc:date>
      <dc:date>2017</dc:date>
      <dc:date>2017-10-02</dc:date>
      <dc:type>conference output</dc:type>
      <dc:identifier>http://hdl.handle.net/10630/14558</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:relation>17 Congreso Nacional de la Sociedad Española de Neurociencias</dc:relation>
      <dc:relation>Alicante, España</dc:relation>
      <dc:relation>Septiembre 2017</dc:relation>
      <dc:rights>open access</dc:rights>
      <dc:rights>by-nc-nd</dc:rights>
   </ow:Publication>
</rdf:RDF>
</metadata></record></GetRecord></OAI-PMH>